| Breast Cancer |
1 |
1 |
| Advanced and Metastatic Breast Cancer |
0 |
0.92 |
| HER2-Positive Breast Cancer |
0 |
0.85 |
| Ovary |
0 |
0.85 |
| Biologic Therapy |
0 |
0.74 |
| Estrogen Receptor-Positive (ER+) Breast Cancer |
0 |
0.74 |
| Cancer |
0 |
0.58 |
| Targeted Cancer Therapy |
0 |
0.58 |
| Breast |
0 |
0.56 |
| Bone Metastasis |
0 |
0.47 |
| Metastasis |
0 |
0.47 |
| Selective Estrogen Receptor Modulators |
0 |
0.44 |
| Genomic Medicine |
0 |
0.36 |
| Endocrine Therapy |
0 |
0.22 |
| Humanized Monoclonal Antibody |
0 |
0.17 |
| Ovarian Ablation |
0 |
0.75 |
| Chemotherapy |
0 |
0.14 |
| Receptors |
0 |
0.14 |
| Epidermal Growth Factor Receptor |
0 |
0.12 |
| Aromatase Inhibitors |
0 |
0.11 |
| Adjuvant Therapy |
0 |
0.08 |
| Bisphosphonate |
0 |
0.55 |
| Healthcare and Medical Technology |
0 |
0.08 |
| Taxane |
0 |
0.55 |